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To the Editor: Thirty-eight patients with Mycobacte-
rium bovis BCG–associated osteomyelitis/osteitis, includ-
ing 8 who were previously reported (1), were identified 
during Taiwan’s vaccine injury compensation program 
during 1989–2012; a total of 30 (79%) patients applied 
for compensation during 2009–2012 (Figure). In Taiwan, 
a laboratory program to differentiate BCG from other spe-
cies of the M. tuberculosis complex, using a kit for the To-
kyo-172 vaccine strain spoligotyping, was established in 
2004 (1). Since 2008, the isolated extrapulmonary tubercu-
losis strains and pathologic specimens collected from chil-
dren <5 years of age have been sent to the national refer-
ence mycobacterial laboratory for BCG detection (2). The 
detected incidence of BCG osteitis/osteomyelitis increased 
from 3.68 cases per million vaccinations during 2002–2006 
to 30.1 per million during 2008–2012.
Parents or guardians signed written consent forms on 
behalf of the children when they submitted claims for the 
vaccine injury compensation program. After consent, chil-
dren’s hospital information was stored in the Taiwan Cen-
ters for Disease Control database and used for research.
Of the 38 compensated BCG osteomyelitis/osteitis pa-
tients, 18 were boys. According to chart review, no patients 
had immunodeficiency or other underlying conditions; 
however, 3 were premature babies (born at 34–36 weeks 
of gestation). Eighteen (47%) children had received BCG 
at <1 week of age, 12 (32%) at 1–4 weeks, 7 (18%) at 1–2 
months, and 1 at >2 months. The average age at inocula-
tion was 16.2 ± 16.6 days. Symptoms or signs began 3–32 
months (average 12.4 ± 6.1 months) after BCG vaccina-
tion; for 68%, symptoms or signs developed 7–18 months 
after vaccination (online Technical Appendix Figure, http://
wwwnc.cdc.gov/EID/article/21/3/14-0789-Techapp1.pdf). 
Time from vaccination to onset of symptoms or signs did 
not differ for the 3 premature infants.
As in previous reports (3,4), extremity bones were 
more commonly involved than axial bones. For 30 (79%) 
children, extremity bones were involved: 14 right lower 
limbs, 7 left lower limbs, 6 left upper limbs, and 3 right up-
per limbs. The tibia was the most common site (9 patients), 
followed by ankle bones (8 patients), femur (4 patients), 
radius and thumb (3 patients each), humerus and knee (2 
patients each), and ulna (1 patient). Of these, 2 patients had 
2 bony lesions. In 8 (21%) children, axial bones were in-
volved: 5 sternums, 2 thoracic vertebrae, and 1 right rib. 
Presentation included a mass (25 [66%] children), tender-
ness (22 [58%]), limping (19 [50%]), redness (14 [37%]), 
and heat (7 [18%]). Average time from first clinical visit to 
final surgical management was 1.6 ± 2.1 months.
Eight (53%) of 15 patients had positive tuberculin 
skin test results. No specific abnormalities were found 
with regard to blood cell counts and inflammation mark-
ers or to chest radiographs, except for 1 child with rib 
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Figure. Number of patient applications for compensation as 
a result of Mycobacterium bovis BCG osteomyelitis/osteitis to 
vaccine injury compensation program, Taiwan, 1998–2012.
erosion. Pathologic diagnosis of Mycobacterium infec-
tion from bony specimens was recorded for 35 (92%) pa-
tients. For 29 (76%), diagnosis was conducted by molecu-
lar study, including 25 (66%) by the national reference 
mycobacterial laboratory. For 4 patients, diagnosis was 
confirmed by culture of M. bovis. Osteomyelitis/osteitis 
for 5 patients was considered BCG related according to 
pathologic diagnosis of Mycobacterium infection, BCG 
vaccination history, and lack of a history of contact with a 
person with tuberculosis.
Thirty-two (84%) children underwent surgery (exci-
sion, debridement, open biopsy), 4 children received ar-
throtomy (3 ankle and knee joint), and 2 children underwent 
only aspiration biopsy. All patients received isoniazid and 
rifampin therapy; 33 patients also received pyrazinamide, 
and 6 received additional ethambutol therapy. Medications 
were adjusted after diagnoses changed from tuberculosis 
to BCG infection. Two patients had major sequelae, both 
involving the thoracic spine and causing severe kyphosis.
Adverse reactions after BCG vaccination depend 
on the BCG dose, vaccine strain, vaccine administration 
method, injection technique, and recipient’s underlying 
immune status (5). The vaccine strain and manufacturing 
process in Taiwan did not change during the study period. 
Findings were not associated with a specific batch of vac-
cine, inoculation age, underlying disease, or Salmonella 
spp. infection. Patients had no common birth place, hospi-
tal, or area of residence. We believe the increased number 
of cases resulted mainly from policy changes and labora-
tory facility improvements.
A surgical approach to obtain a specimen is indicated. 
However, because medical treatment usually yields a good 
outcome (6), extensive debridement should be avoided. 
Although some patients with lower extremity involvement 
initially limped, most were able to walk well later. Vertebral 
involvement is rare. Unlike previously reported cases (7,8), 
both patients reported here who had vertebral involvement 
had sequelae. For young children with suspected vertebral 
tuberculosis but no tuberculosis contact history, a biopsy 
specimen for BCG studies is preferable to spondylectomy. 
Although no definite immunologic deficit was found in 
these BCG osteomyelitis/osteitis patients, 2 other compen-
sated infants with disseminated BCG during the same peri-
od in Taiwan had identified immunodeficiency (9). Studies 
are ongoing by the Taiwan Centers for Disease Control to 
evaluate medical treatment duration, long-term outcomes, 
and more detailed immune genetic tests.
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